DLX-2270
Chemical compound
From Wikipedia, the free encyclopedia
DLX-2270 is an experimental serotonin receptor modulator which is under investigation for the potential treatment of schizophrenia.[1]
- None
| Clinical data | |
|---|---|
| Other names | DLX2270 |
| Routes of administration | Oral[1] |
| Drug class | Serotonin 5-HT2A receptor antagonist; Serotonin 5-HT2C receptor agonist; Antipsychotic; Psychoplastogen[1] |
| ATC code |
|
It acts as a serotonin 5-HT2A receptor antagonist and serotonin 5-HT2C receptor agonist.[1] In contrast to conventional antipsychotics, DLX-2270 is not a dopamine D2 receptor antagonist.[1] The drug is orally active and centrally penetrant.[1] In preclinical research, DLX-2270 has psychoplastogenic effects.[1] It reverses hyperlocomotion and social interaction deficits induced by the NMDA receptor antagonist phencyclidine (PCP).[1] In contrast to serotonin 5-HT2A receptor agonists, DLX-2270 does not produce the head-twitch response in rodents, and hence would not be expected to be hallucinogenic in humans.[1]
DLX-2270 was first described in the scientific literature in 2025.[1] It is under development by Delix Therapeutics.[1] DLX-2270 is a small molecule, but its chemical structure does not yet appear to have been disclosed.[1]
See also
- List of investigational hallucinogens and entactogens
- JRT
- Zalsupindole (DLX-001, AAZ-A-154)
- DLX-159
- Tabernanthalog (DLX-007)